<DOC>
	<DOCNO>NCT02397837</DOCNO>
	<brief_summary>Converging evidence suggest patient bipolar disorder suffer deficit neurocognitive functioning persist , despite remission acute affective symptom . These impairment contribute directly functional disability , highlight need intervention beyond standard treatment order achieve full inter-episode recovery . The current study aim investigate safety efficacy dopamine agonist ( pramipexole ) , persistent cognitive abnormality euthymic bipolar patient use placebo-controlled , adjunctive , 12-week trial design .</brief_summary>
	<brief_title>Targeting Cognition Bipolar Disorder With Pramipexole</brief_title>
	<detailed_description>All eligible participant undergo study visit screen , baseline ( week 0 ) , week 1 , week 2 , week 3 , week 4 , week 6 , week 8 , week 12 , ( end study ) . Randomization conduct via computer generate program study staff blind unless un-blinding require safety reason . Subjects randomize 1:1 ratio stratification concomitant antipsychotic status depression baseline ( HRSD &lt; 8 v &gt; 8 ) . Study drug blind match placebo . Adapting previous work BD accord package labeling , dosage titration schedule slow flexible . Dosing initiate 0.25 mg QHS night one , follow 0.25 mg BID day two onward , increase every week target 4.5 mg/day . As compare previous maximum 1.5 mg/day ( Burdick et al . 2012 ) , opt allow 4.5 mg/day ( maximum approve dosage Parkinson 's disease ) ensure adequate target engagement . We familiar dose range , 4.5 mg/day allow study BD depression ( Goldberg et al . 2004 ) . Dosing flexible base side effect ; however , 1.5 mg/day tolerate , subject discontinue . Titration occur week 6 effort make maintain dose completion trial ( week 12 ) .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Bipolar Disorder</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<criteria>Inclusion criterion : Age 1865 DSMIV BD I II diagnosis Affective stability , define Young Mania Rating Scale ( YMRS ) rating &lt; 8 Hamilton Depression Rating Scale ( HRSD ) rating &lt; 16 screen baseline . We require subsyndromal depression significantly worsen 4 week prior randomization avoid enrol subject verge full depressive episode . Evidence clinicallysignificant neurocognitive impairment screen Clinicallyacceptable , stablydosed , mood stabilize medication regimen &gt; 1 month prior enrollment , medication change plan 12week study period . History CNS trauma , neurological disorder , ADHD , learn disability Positive urine toxicology DSMIV diagnosis substance abuse/dependence within 3 month Active , unstable medical problem may interfere cognition Recent history rapidcycling Abnormal lab ECG result screen History heart failure Significant suicidal risk ( HRSD item 3 &gt; 2 clinical judgment ) Estimated IQ MR range per Wide Range Achievement Test ( WRAT ) standard score le 70 Pregnant woman woman child bear potential use medically accept mean contraception ( include oral contraceptive implant , condom , diaphragm , spermicide , intrauterine device , tubal ligation , partner vasectomy ) Women breastfeed Participation investigational cognitive enhancement study within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Bipolar Disorder</keyword>
	<keyword>Cognition</keyword>
</DOC>